Lynne Katzmann Acquires Shares in Sabra Health Care REIT
Lynne Katzmann bought 8,310 shares of Sabra Health Care REIT on June 17, 2026.
Key Points
- Lynne Katzmann purchased 8,310 shares of Sabra Health Care REIT on June 17, 2026.
- Sabra Health Care REIT, trading at $18.12, has a market cap of $4.57 billion and a P/E ratio of 28.76.
- Analysts have set a mean price target of $22.54 for Sabra, with a recommendation to buy.
Lynne Katzmann made a notable move by acquiring 8,310 shares of Sabra Health Care REIT, Inc. (NasdaqGS:SBRA) on June 17, 2026. This insider purchase reflects confidence in the company's prospects.
Insider Buying and Selling at Sabra Health Care REIT, Inc.
Several insiders, including Lynne Katzmann, Ann Kono, Catherine Cusack, Michael Foster, Jeffrey Malehorn, and Craig Barbarosh, each bought 8,310 shares of Sabra Health Care REIT on June 17, 2026. These transactions were not conducted under Rule 10b5-1 plans.
Other Institutional Activity in Sabra Health Care REIT
BlackRock, Inc. increased its holdings by 704,770 shares, ending with 39,098,389 shares valued at approximately $751.9 million. Principal Financial Group Inc added 98,770 shares to hold a total of 25,052,121 shares worth about $481.8 million. State Street Corp grew its position by 198,311 shares, now holding 12,099,951 shares valued at $232.7 million. Meanwhile, JPMorgan Chase & Co significantly boosted its holdings by 5,569,621 shares, totaling 8,201,220 shares valued at $159.4 million.
Sabra Health Care REIT Stock Snapshot
Shares of Sabra Health Care REIT are trading around $18.12. The company boasts a market cap of $4.57 billion and a P/E ratio of 28.76. The stock's 52-week range is between $17.17 and $21.28, with a 50-day moving average of $19.94 and a 200-day moving average of $19.31. Sabra has a beta of 0.626, indicating lower volatility compared to the market.
Recent Earnings
Sabra Health Care REIT reported revenue of $815.7 million, with a revenue growth rate of 21.7%. The company achieved a net margin of 19.15% and a return on equity of 5.68%. The next earnings report is expected on August 3, 2026.
Analysts Set New Price Targets
On June 18, 2026, Scotiabank maintained its hold rating on Sabra with a price target of $19.0. Wells Fargo, on June 1, 2026, reiterated its buy rating, setting a price target of $23.0. The consensus among 13 analysts is a buy recommendation, with a mean price target of $22.54.
About Sabra Health Care REIT, Inc.
Sabra Health Care REIT, Inc. is a real estate investment trust focused on owning and investing in healthcare-related properties across the United States and Canada. Headquartered in Tustin, California, the company is led by CEO Richard K. Matros and employs 58 people. Sabra operates as a self-administered and self-managed REIT, providing real estate solutions for the healthcare industry since its incorporation in 2010.
Bottom Line
Lynne Katzmann's recent purchase of Sabra Health Care REIT shares underscores a positive outlook for the company. Investors keep a close eye on such insider activities for potential insights into company health. As always, it's important to remember that insider transactions are just one piece of the puzzle, and investors should consider a variety of factors when evaluating a stock.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.
